ORIGINAL RESEARCH article
Front. Oncol.
Sec. Gastrointestinal Cancers: Gastric and Esophageal Cancers
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1498388
Evaluation of the Feasibility, Safety, and Preliminary Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Following Radical Surgery for Locally Advanced Gastric Cancer
Provisionally accepted
- 1The Second Hospital of Shandong University, Jinan, China
- 2Shandong Cancer Hospital, Shandong University, Jinan, Shandong Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To explore the feasibility, safety, and potential association between hyperthermic intraperitoneal chemotherapy (HIPEC) and peritoneal recurrence in patients with locally advanced gastric cancer following D2 radical surgery. Materials and methods: A retrospective analysis was conducted on 156 patients with locally advanced gastric cancer treated with D2 surgery at two centers between 2014 and 2023. Clinical outcomes and adverse events were assessed. Results: Baseline characteristics were comparable between the HIPEC group (n = 70) and the surgery-only group (n = 86). The 2-year peritoneal recurrence rate was lower in the HIPEC group (18.6% vs. 34.9%, P=0.0206). Several factors—including high Charlson Comorbidity Index, advanced T stage, vascular invasion, intraoperative blood loss, and absence of HIPEC—were associated with higher recurrence risk. No significant differences were observed in perioperative complications between the groups or among different HIPEC frequencies (all P > 0.05). Conclusion: In this real-world dual-center study, HIPEC following D2 surgery was found to be feasible and safe, and was associated with a reduced risk of peritoneal recurrence in patients with locally advanced gastric cancer. These observational findings warrant further validation in randomized controlled trials.
Keywords: intraperitoneal hyperthermic chemotherapy, gastric cancer, Advanced Stage, survival analysis, Peritoneal metastasis recurrence
Received: 18 Sep 2024; Accepted: 20 Aug 2025.
Copyright: © 2025 Zhang, Yu, Wang, Zhao, Zhao, Chai and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dehai Wang, The Second Hospital of Shandong University, Jinan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.